ABSTRACT
We present a 29-year-old woman with pT2N0M0 breast cancer, histological diagnosis of invasive ductal carcinoma, ER and PR low positive, and HER-2 (3+). The patient developed trastuzumab-induced thrombocytopenia in 6 hours after an intravenous infusion of trastuzumab at the second cycle of trastuzumab treatment with the symptom of abnormal uterine bleeding. Laboratory exam revealed a sharp drop of platelet count down to 3×10
ABSTRACT
Implant-based breast reconstruction is the most common choice in breast cancer patients. Recently,the acellular dermal matrix (ADM) technique has been widely used in implant-based breast reconstruction in the western countries. This article briefly reviews the biological characteristics,history,types,surgical techniques,and postoperative complications of ADM.
Subject(s)
Female , Humans , Acellular Dermis , Breast Implantation , Breast Implants , Breast Neoplasms , General Surgery , Mastectomy , Postoperative ComplicationsABSTRACT
<p><b>OBJECTIVE</b>To evaluate the value of cardiac troponin I (CTnI) measurement in predicting anthracycline-induced cardiotoxicity in patients with breast cancer.</p><p><b>METHODS</b>This study was conducted among 186 breast cancer patients receiving anthracycline-based chemotherapy. Serum cTnI concentrations before and after each cycle of the chemotherapy and the left ventricular ejection fraction (LVEF) before and at the 2nd, 4th and 6th months of the treatment were recorded. According to serum cTnI concentration, the patients were divided into CTnI+ group (with serum CTnI concentration of no less than 0.1 ng/ml, n=60) and CTnI- (<0.1 ng/ml) group (n=126).</p><p><b>RESULTS</b>No patients in this series experienced cardiac heart failure (CHF). The number of patients with a LVEF reduction by over 10% from the baseline was 16 (26.7%) in CTnI+ group, as compared to 7 (5.6%) in CTnI- group, showing a significant difference between the two groups (P<0.01).</p><p><b>CONCLUSION</b>CTnI can be a useful marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.</p>
Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Young Adult , Anthracyclines , Therapeutic Uses , Antibiotics, Antineoplastic , Therapeutic Uses , Biomarkers , Blood , Breast Neoplasms , Drug Therapy , Cardiotoxins , Myocardium , Metabolism , Troponin I , BloodABSTRACT
<p><b>OBJECTIVE</b>To analyze the clinical symptoms of patients with hyperparathyroidism.</p><p><b>METHODS</b>The clinical data of 455 patients with hyperparathyroidism who were treated in Peking Union Medical College Hospital from October 1974 to January 2009 were retrospectively analyzed.</p><p><b>RESULTS</b>Out of these 455 patients, there were 156 men (34.3%) and 299 women (65.7%), and the male/female ratio was 1:1.92. The mean onset age was (40.33±16.61) years (range: 5-86 years). Most patients (n=372, 81.8%) with skeletal manifestations, of whom 283 patients (62.2%) presented with ostealgia. The second most common symptom (n=252, 55.4%) was in urinary system, of whom 162 patients (35.6%) had nephrolithiasis. There were 200 patients (44.0%) with digestive system symptoms and 54 patients (11.9%) with neuropsychological symptoms. Twenty-one patients (4.6%) had asymptomatic hyperparathyroidism. There were 133 patients (29.2%) with decreased body height, and the mean decrease was(6.23±5.02)cm. Forty-nine patients (10.8%) presented with hypercalcemia crisis.</p><p><b>CONCLUSIONS</b>Women are more susceptible to hyperparathyroidism, which is featured by symptoms in skeletal system, urinary system, and digestive system. The asymptomatic hyperparathyroidism is relatively rare, which should be carefully considered during clinical practice.</p>